Articles with public access mandates - James J Harding, MDLearn more
Not available anywhere: 7
Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype
MA Lowery, EJ Jordan, O Basturk, RN Ptashkin, A Zehir, MF Berger, ...
Clinical Cancer Research 23 (20), 6094-6100, 2017
Mandates: US National Institutes of Health
Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma
JJ Harding, G Abu-Zeinah, JF Chou, DH Owen, M Ly, MA Lowery, ...
Journal of the National Comprehensive Cancer Network 16 (1), 50-58, 2018
Mandates: US National Institutes of Health
Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial
F Meric-Bernstam, NM Tannir, O Iliopoulos, RJ Lee, ML Telli, AC Fan, ...
Clinical Cancer Research 28 (8), 1540-1548, 2022
Mandates: US National Institutes of Health
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma
D Cowzer, JB White, JF Chou, PJ Chen, TH Kim, DN Khalil, IH El Dika, ...
JCO Precision Oncology 7, e2300272, 2023
Mandates: US National Institutes of Health
Subacute Abdominal Pain in a Patient With Chronic Liver Disease and Hepatocellular Carcinoma
B Zheng-Lin, DM Faleck, JJ Harding
JAMA oncology 8 (11), 1688-1689, 2022
Mandates: US National Institutes of Health
Reply to:“Adjuvant medications that improve survival after locoregional therapy.”
FE Boas, E Ziv, H Yarmohammadi, KT Brown, JP Erinjeri, CT Sofocleous, ...
Journal of vascular and interventional radiology: JVIR 28 (9), 1335, 2017
Mandates: US National Institutes of Health
Genomics and Interventional Oncology in Primary Liver Cancer
R Slovak, MD Case, HS Kim
Digestive Disease Interventions 4 (01), 053-059, 2020
Mandates: US Department of Defense
Available somewhere: 84
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ...
Nature medicine 23 (6), 703-713, 2017
Mandates: US National Institutes of Health
OncoKB: a precision oncology knowledge base
D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ...
JCO precision oncology 1, 1-16, 2017
Mandates: US National Institutes of Health
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ...
Nature 554 (7691), 189-194, 2018
Mandates: US National Institutes of Health
Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies
JJ Harding, S Nandakumar, J Armenia, DN Khalil, M Albano, M Ly, J Shia, ...
Clinical Cancer Research 25 (7), 2116-2126, 2019
Mandates: US National Institutes of Health
Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention
MA Lowery, R Ptashkin, E Jordan, MF Berger, A Zehir, M Capanu, ...
Clinical Cancer Research 24 (17), 4154-4161, 2018
Mandates: US National Institutes of Health
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
Mandates: US National Institutes of Health
TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma
L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ...
Cancer discovery 9 (8), 1064-1079, 2019
Mandates: US Department of Defense, US National Institutes of Health, V Foundation, USA
Progression of RAS-mutant leukemia during RAF inhibitor treatment
MK Callahan, R Rampal, JJ Harding, VM Klimek, YR Chung, T Merghoub, ...
New England Journal of Medicine 367 (24), 2316-2321, 2012
Mandates: US National Institutes of Health
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana‐Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan …
JJ Luke, MK Callahan, MA Postow, E Romano, N Ramaiya, M Bluth, ...
Cancer 119 (20), 3687-3695, 2013
Mandates: US National Institutes of Health
First-in-humans imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting
N Pandit-Taskar, MA Postow, MD Hellmann, JJ Harding, CA Barker, ...
Journal of Nuclear Medicine 61 (4), 512-519, 2020
Mandates: US National Institutes of Health
Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection
W Park, J Chen, JF Chou, AM Varghese, KH Yu, W Wong, M Capanu, ...
Clinical Cancer Research 26 (13), 3239-3247, 2020
Mandates: US National Institutes of Health
Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition
JJ Harding, MA Lowery, AH Shih, JM Schvartzman, S Hou, C Famulare, ...
Cancer discovery 8 (12), 1540-1547, 2018
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a …
A Cercek, T Boerner, BR Tan, JF Chou, M Gönen, TM Boucher, ...
JAMA oncology 6 (1), 60-67, 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program